MGI PHARMA (MOGN) Presents Interim Gliadel Wafer Clinical Data
More News related to MOGN
- S&P Announces Changes to U.S. Index
- MGI PHARMA (MOGN) sNDA for Aloxi Capsules Accepted for Review By the FDA
- MGI PHARMA (MOGN) Said Aquavan NDA Accepted for Review by FDA
- Unusual 11 Mid-Day Movers: MBIA, PMI Higher; Celegene Lower on Clinical Results (MBI, PMI, CELG)
- Notable Analyst Rating Changes: CC, GMST, FL Up; EMR, PALM, MOGN Down
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
MGI PHARMA, INC. (Nasdaq: MOGN) summarized interim results from a phase 2 combination study of Gliadel Wafer in patients with newly-diagnosed, resectable, high grade malignant gliomas presented at the 2006 Society for Neuro-Oncology Annual Meeting. Interim data from 35 patients with this aggressive brain tumor showed a median survival of 18.6 months when Gliadel Wafer and temozolomide are used in combination with surgery and radiotherapy.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
